Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2019-05-17 Major Shareholding Noti…
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2019-05-17 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the first quarter ended March 31, 2019. The document itself does not contain detailed financial statements or comprehensive financial analysis but rather furnishes a press release as an exhibit. The length of the document is 3207 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, a document that announces financial results via a press release and is short should be classified as an Earnings Release (ER).
2019-05-10 English
FORM 10-Q
Interim / Quarterly Report Q1 2019
2019-05-10 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It details the terms of the offering, underwriting discounts, use of proceeds, risk factors, and other information relevant to the securities offering. It is not a financial report, earnings release, management discussion, or any other type of corporate report. Instead, it is a capital markets document announcing and describing a financing transaction. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a financing update rather than a brief announcement or regulatory filing. Confidence is high given the clear identification of the document as a prospectus supplement for a stock offering.
2019-05-01 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2019, by Mustang Bio, Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of common stock. The document details the terms of the offering, the parties involved, and includes exhibits such as the underwriting agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising transaction and related agreements. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2019-04-30 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about voting methods, meeting details, and proposals to be voted on, such as election of directors and ratification of auditors. This type of document is used to solicit shareholder votes and provide information necessary for voting decisions. It is not the actual proxy statement itself but additional materials related to the proxy solicitation. According to the filing definitions, proxy solicitation and information statements fall under the category 'PSI'. The document length and content confirm it is not a brief announcement or a full annual report but a proxy solicitation document.
2019-04-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.